伊立替康联合氟尿嘧啶/亚叶酸钙方案一线治疗37例晚期大肠癌  

Irinotecan plus fuorouracil/ leucovorin as the first-line in treatment of 37 patients with advanced colorectal cancer

作　　者：张弘纲[1] 吴芳[1] 陈闪闪[1] 

机构地区：[1]中国医学科学院中国协和医科大学附属肿瘤医院(研究所)内科,北京100021

出　　处：《中国癌症杂志》2006年第12期1055-1056,共2页China Oncology

摘　　要：背景与目的:伊立替康联合氟尿嘧啶/亚叶酸钙方案为晚期大肠癌一线治疗的标准方案。本研究观察伊立替康联合氟尿嘧啶/亚叶酸钙双周(CPT-11+5FU/LV双周FOLFIR I)方案一线治疗晚期大肠癌的客观有效率及不良反应。方法:2001年5月—2005年3月,37例晚期大肠癌患者接受FOLFIR I方案一线治疗。化疗剂量为CPT-11 180 mg/m2静脉点滴第1天,亚叶酸钙(LV)200 mg/m2静脉点滴第1、2天,5-FU 400 mg/m2静推第1、2天,5-FU 600 mg/m2持续泵注44小时第1、2天,14天为1周期。结果:36例可评价疗效患者有效率为41.7%。Ⅲ/Ⅳ度骨髓抑制发生率占总人数的35.1%和8.1%,4例患者出现中性粒细胞减少性发热。Ⅲ度迟发性腹泻发生率为8.1%。结论:伊立替康联合氟尿嘧啶/亚叶酸钙双周方案(FOLFIR I)是一线治疗晚期大肠癌安全而有效的方案。Background and purpose： Irinotecan plus fuorouracil/Leucovorin has beeome the standard regimen as the first-line in treating advanced colorectal cancer. We investigated the clinical response and side-effects of the first-line treatment with Irinotecan plus fuorouracil/leucovorin（FOLFIRI） for advanced colorectal cancer. Methods： From may 2001 to march 2005, 37 patients with advanced colorectal cancer were treat with irinotecan 180mg/m^2 i. v. on day 2, and fuorouracil 400 mg/m^2, bolus on day 1,2 and 1200 mg/m^2, civ. 44hour; leucovorin 200 mg/m^2 i. v. on day 1 , 2, two weeks per cycle. Results： The response rate was 41.7%. Incidence of Ⅲ/Ⅳ Grade myelosuppression was 35.1%/8.1%, and 4 patients suffered from febrile neutropenia . Incidence of Ⅲ Grade delayed diarrhea was 8. 1%. Conclusions： The first-line chemotherapy with a combination of irinotecan and fuorouracil/leueovorin is effictive and well tolerated by patients with advanced colorectal cancer.

关 键 词：晚期大肠癌 药物疗法 伊立替康 氟尿嘧啶 

分 类 号：R735.3[医药卫生—肿瘤]